

Welcome to our investor page



Breadcrumb

1. Investors

Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes mRNA vaccines, cell and gene therapies, targeted antibodies, small molecule immunomodulators, ribologicals, and next-generation immunomodulators. Our approach has created a robust and diversified product pipeline across infectious disease and oncology, including our first commercial product, COMIRNATY, our COVID-19 vaccine. COMIRNATY is the first ever approved mRNA drug product. Our clinical pipeline includes more than 25 product candidates in oncology and infectious diseases. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. We believe we are well-positioned to develop and commercialize the next generation of immunotherapies with the potential to transform treatment paradigms for many severe diseases.

Press Releases

22 August 2024

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

>

Read on

19 August 2024

Lift of Partial Clinical Hold for BNT326/YL202



Read on

16 August 2024

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age



Read on

5 August 2024

BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update



Read on

30 July 2024

BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma



Read on

FRONT > Events - View All



[View All Events](#)

Stock quote

BNTX | Aug 23, 2024

\$88.08 / +0.97%

Data Provided by Refinitiv. Minimum 15 minutes delayed.



Email Alerts

© 2024 BioNTech
All rights reserved